DYN
Dyne Therapeutics, Inc.
NASDAQ · USHealthcareBiotechnology
$23.45-1.22%
Price as of Jul 20, 2026
DYN growth
Dyne Therapeutics, Inc. growth
Reported trailing growth, forward expectations and three-year compound growth rates.
Trailing growth
Year over year
- Revenue
- —
- EBITDA
- -13.3%
- EBIT
- -18.6%
- EPS
- +10.3%
- Free cash flow
- -43.1%
- Operating cash flow
- -38.3%
Forward estimates
- Revenue
- —
- EBITDA
- —
- EPS
- +50.2%
Three-year CAGR
- Revenue
- —
- EBITDA
- -39.0%
- EBIT
- -36.1%
- Net income
- -40.6%
- EPS
- -3.0%
- Free cash flow
- -37.4%
Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.